The main results of the SUMMIT trial, reported last year, showed that tirzepatide—a dual glucose-dependent insulinotropic ...

The peptide structure of Tirzepatide includes modifications that are believed to increase its stability and extend its activity, potentially leading to more sustained metabolic impacts.

Adults with type 2 diabetes receiving tirzepatide had significantly greater declines in urine albumin-to-creatinine ratio ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

A retrospective case series identified nine patients who developed ophthalmic complications during treatment with semaglutide ...

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...

Hines Jr Professor of Medicine at Yale University School of Medicine Tirzepatide decreases heart size to improve cardiac structure, function In a secondary analysis of the SUMMIT trial ...

Tirzepatide combines synthetic mimics of two ... Importantly, this "type of therapy does not interfere with the normal structure of the body" unlike endoscopic surgery or bariatric surgery ...